Related Experiment Video
Updated: Apr 21, 2026
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
To treat or not to treat: developments in the field of advanced differentiated thyroid cancer
T C Schneider1, E Kapiteijn, E P Corssmit
1Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Background:
Thyroid cancer is the most prevalent endocrine malignancy. Based on the increased understanding of thyroid tumourigenesis, novel therapeutic agents have been identified. However, given the low incidence, the good prognosis of the majority of these tumours and the limited evidence of different treatment modalities, a wide variety of treatment strategies are available. These are mostly based on small studies, data from retrospective analyses and the particular experiences of treating physicians. We discuss the recent developments in the treatment of advanced differentiated thyroid cancer.
Case Description:
Three cases demonstrate the considerations involved in treatment decisions for patients with advanced thyroid cancer. The first patient achieved stable disease for over five years with different targeted therapies. The second patient shows the potential (severe) toxicity of these drugs and the third patient illustrates the indolent nature of this disease.
Conclusion:
The treatment of patients with extensively metastasised thyroid cancer is very complicated. The timing of initiation of therapy and the potential toxicity of targeted therapies are important in the clinical decision to treat or not to treat because of the slowly progressive course of differentiated thyroid cancer. When targeted therapy is considered, it remains of great importance to enrol patients in clinical studies in order to further determine the position of these therapies, to develop more effective (combination) treatment schemes, and above all, to identify those patients that truly benefit.
Insights
Advanced differentiated thyroid cancer treatment is complex. Targeted therapies offer options but require careful timing and toxicity monitoring, emphasizing the need for clinical trials to optimize patient benefit.
Area of Science:
- Endocrinology
- Oncology
Background:
- Thyroid cancer is the most common endocrine malignancy.
- Recent advances in understanding thyroid tumorigenesis have led to novel therapeutic agents.
- Treatment strategies for advanced differentiated thyroid cancer are diverse, often based on limited evidence.
Observation:
- Case studies highlight varied responses to targeted therapies in advanced thyroid cancer.
- One patient achieved long-term stable disease with targeted agents.
- Other cases illustrate significant drug toxicity and the disease's indolent nature.
Findings:
- Treating extensively metastasized thyroid cancer presents significant challenges.
- The timing of therapy initiation and potential toxicity of targeted agents are critical decision factors.
- The slow progression of differentiated thyroid cancer influences treatment choices.
Implications:
- Enrolling patients in clinical studies is crucial for advancing targeted therapy efficacy.
- Further research is needed to develop optimal combination treatments.
- Identifying patients who will truly benefit from targeted therapies is a key goal.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...